Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: November 24, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing regarding director interests and does not contain financial statements.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this document.
Guidance, Outlook, and Disclosures
Exhibit Submitted: Exhibit 99.1 - Final Director's Interest Notice for Meltzer.
Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Management Commentary: The filing is signed by Julian Babarczy, Chairman, on behalf of the registrant.
Investor Verification Checklist
- Verify the details of the Director's Interest Notice (Exhibit 99.1) regarding "Meltzer" to understand potential conflicts or holdings.
- Review the referenced Form S-8 and Form F-3 registration statements for details on equity plans and capital raising activities.
- Confirm the company's status as a "development stage enterprise" and its current cash runway via the most recent Form 20-F or quarterly reports, as this 6-K contains no financial data.